Early detection of cervical carcinomas;Früherkennung des zervixkarzinoms

Deutsches Arzteblatt

Volumn 105, Issue 37, 2008, Pages 617-622

  Wentzensen, Nicolas ^a   Klug, Stefanie J ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Biomarker; Cancer screening; Cervical cancer; Cytology; HPV; HPV vaccination

Indexed keywords

CANCER DIAGNOSIS; CANCER SCREENING; HEALTH PROGRAM; HUMAN; MEDICAL DOCUMENTATION; QUALITY CONTROL; REVIEW; UTERINE CERVIX CARCINOMA; VACCINATION; WART VIRUS;

EID: 54249084504     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2008.0617     Document Type: Review

References (25)

1. Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24: 11-25.
2. Munoz N, Bosch FX, de Sanjosé S et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
3. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
4. Ostor AG: Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186-92.
5. Schiffman M: Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007; 111: 145-53.
6. Doorbar J: Papillomavirus life cycle organization and biomarker selection. Dis Markers 2007; 23: 297-313.
7. von Knebel Doeberitz M: New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002; 38: 2229-42.
8. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
9. Klug SJ, Blettner M: Zervixkarzinom, HPV- Infektion und Screening. Dtsch Arztebl 2003; 100(3): 132-6.
10. Schenck U, von Karsa L: Cervical cancer screening in Germany. Eur J Cancer 2000; 36: 2221-6.
11. Wright TC, Schiffman M, Solomon D et al.: Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004; 103: 304-9.
12. Klug SJ, Hukelmann M, Hollwitz B et al.: Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 2007; 79: 616-25.
13. Löning M, Gissmann L, Diedrich K, Friese K, Kreienberg R, Hillemanns P: Humanpathogene Papillomviren und Zervixkarzinom. Dtsch Arztebl 2007; 104(41): 2806-10.
14. Franco EL, Cuzick J: Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008; 26: 16-23.
15. Wiener HG, Klinkhamer P, Schenck U et al.: European guidelines for quality assurance in cervical cancer screening: recommendations for cytology laboratories. Cytopathology 2007; 18: 67-78.
16. Davey E, Barratt A, Irwig L et al.: Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006; 367: 122-32.
17. Brink AA, Snijders PJ, Meijer CJ: HPV detection methods. Dis Markers 2007; 23: 273-81.
18. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J: Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96: 280-93.
19. Mayrand MH, Duarte-Franco E, Rodrigues I et al.: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-88.
20. Naucler P, Ryd W, Tornberg S et al.: Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
21. Wentzensen N, von Knebel Doeberitz M: Biomarkers in cervical cancer screening. Dis Markers 2007; 23: 315-30.
22. Lie AK, Risberg B, Borge B et al.: DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 2005; 97: 908-15.
23. Klaes R, Friedrich T, Spitkovsky D et al.: Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84.
24. Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M: Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer 2007; 111: 58-66.
25. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M: Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007; 197: 356.